Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Kurland S, Furebring M, Löwdin E, Eliasson E, Nielsen EI, Sjölin J.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02466-18. doi: 10.1128/AAC.02466-18. Print 2019 Jun.

PMID:
30962329
2.

[Cross allergy between penicillins and other beta lactam antibiotics--the risk is much less than previously thought].

Tängden T, Furebring M, Löwdin E, Werner S.

Lakartidningen. 2015 Feb 3;112. pii: C9A4. Review. Swedish.

3.

Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.

Tängdén T, Adler M, Cars O, Sandegren L, Löwdin E.

J Antimicrob Chemother. 2013 Jun;68(6):1319-26. doi: 10.1093/jac/dkt044. Epub 2013 Mar 10.

PMID:
23478794
4.

Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration.

Lignell A, Löwdin E, Cars O, Chryssanthou E, Sjölin J.

Antimicrob Agents Chemother. 2011 Jul;55(7):3099-104. doi: 10.1128/AAC.01671-10. Epub 2011 Apr 18.

5.

Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone.

Lignell A, Löwdin E, Cars O, Sanglard D, Sjölin J.

Antimicrob Agents Chemother. 2011 Apr;55(4):1629-37. doi: 10.1128/AAC.00791-10. Epub 2011 Jan 31.

6.

Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.

Tängdén T, Cars O, Melhus A, Löwdin E.

Antimicrob Agents Chemother. 2010 Sep;54(9):3564-8. doi: 10.1128/AAC.00220-10. Epub 2010 Jun 14.

7.

Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.

Lignell A, Löwdin E, Cars O, Sjölin J.

J Antimicrob Chemother. 2008 Jul;62(1):142-8. doi: 10.1093/jac/dkn154. Epub 2008 Apr 12.

PMID:
18408237
9.

Propensity to release endotoxin after two repeated doses of cefuroxime in an in vitro kinetic model: higher release after the second dose.

Goscinski G, Tano E, Löwdin E, Sjölin J.

J Antimicrob Chemother. 2007 Aug;60(2):328-33. Epub 2007 Jun 13.

PMID:
17567631
10.
11.

Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.

Nielsen EI, Viberg A, Löwdin E, Cars O, Karlsson MO, Sandström M.

Antimicrob Agents Chemother. 2007 Jan;51(1):128-36. Epub 2006 Oct 23.

12.

Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model.

Tano E, Cars O, Löwdin E.

J Antimicrob Chemother. 2005 Jul;56(1):240-2. Epub 2005 May 26.

PMID:
15919770
14.
15.
16.

Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.

Odenholt I, Löwdin E, Cars O.

Antimicrob Agents Chemother. 2003 Oct;47(10):3352-6.

17.

Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model.

Odenholt I, Gustafsson I, Löwdin E, Cars O.

Antimicrob Agents Chemother. 2003 Feb;47(2):518-23.

19.

Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model.

Odenholt I, Löwdin E, Gustafsson I, Cars O.

Antimicrob Agents Chemother. 2002 Jun;46(6):2046-8.

20.

Bactericidal effects of levofloxacin in comparison with those of ciprofloxacin and sparfloxacin.

Odenholt I, Löwdin E, Cars O.

Clin Microbiol Infect. 1998 May;4(5):264-270.

21.

Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model.

Gustafsson I, Löwdin E, Odenholt I, Cars O.

Antimicrob Agents Chemother. 2001 Sep;45(9):2436-40.

22.

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

Odenholt I, Löwdin E, Cars O.

Antimicrob Agents Chemother. 2001 Jan;45(1):23-9.

23.

Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.

Odenholt I, Cars T, Lowdin E.

J Antimicrob Chemother. 2000 Jul;46(1):35-43.

PMID:
10882686
24.
25.
26.
27.
28.

Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model.

Löwdin E, Odenholt I, Bengtsson S, Cars O.

Antimicrob Agents Chemother. 1996 Nov;40(11):2478-82.

29.
30.

A new method to determine postantibiotic effect and effects of subinhibitory antibiotic concentrations.

Löwdin E, Odenholt-Tornqvist I, Bengtsson S, Cars O.

Antimicrob Agents Chemother. 1993 Oct;37(10):2200-5.

31.

Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Odenholt-Tornqvist I, Löwdin E, Cars O.

Antimicrob Agents Chemother. 1992 Sep;36(9):1852-8.

32.

Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro.

Odenholt-Tornqvist I, Löwdin E, Cars O.

Antimicrob Agents Chemother. 1991 Sep;35(9):1834-9.

33.

The postantibiotic effect of cefcanel on beta-hemolytic streptococci group A in vitro and in vivo.

Löwdin E, Tornqvist IO, Cars O.

Scand J Infect Dis Suppl. 1990;74:190-4.

PMID:
2097708

Supplemental Content

Loading ...
Support Center